Ginkgoheterosides (Ginkgo Flavonol Glycosides): A Comprehensive Reference
1. Nomenclature, Identity, and Botanical Source
The term ginkgoheterosides — also rendered as ginkgo-flavone glycosides, ginkgo flavonol glycosides (GFGs), or ginkgo-flavone heterosides — refers collectively to the family of flavonoid glycosides that constitute the principal polyphenolic fraction of standardized extracts derived from the dried leaves of Ginkgo biloba L. (family Ginkgoaceae). The term is used interchangeably in pharmacopoeial, clinical, and commercial contexts with "ginkgo flavone glycosides" or simply "flavonol glycosides," and the ingredient is never isolated commercially as a single pure chemical entity but rather as a defined-percentage fraction within a standardized botanical extract.
Ginkgo biloba extract is defined as a complex product derived from the dried leaves of the Ginkgo biloba tree, known for its pharmacologically active constituents, including flavonol glycosides and terpene lactones. The ginkgo leaf contains numerous biologically active agents, including flavonol and flavone glycosides, diterpene lactones, ginkgolides, sesquiterpenes, iron-based superoxide dismutase, p-hydroxybenzoic acid, ascorbic acid, and catechin.
Ginkgo biloba leaves contain a number of substances from the flavonoid group, including flavonol glycosides, biflavones, proanthocyanidins, and isoflavonoids; the majority, however, are the multiform glycosides of quercetin, kaempferol, and isorhamnetin. One hundred ten flavonoids belonging to seven classes have been identified in ginkgo extracts. The first class consists of 52 glycosides of flavonols and seven flavonols. Known aglycones of flavonol glycosides include quercetin, kaempferol, and isorhamnetin. In addition, from the group of aglycones, there are also syringetin, myricetin, laricitrin, myricetin 3′,4′-dimethyl ether, and patuletin.
The composition of the plant extract is predominated by flavonoids, among which the most represented are flavonol mono-, di-, and triglycosides, which may carry an ester bond with p-coumaric acid. Aglyconic molecular parts of typical ginkgo flavone glycosides are quercetin, kaempferol, and isorhamnetin.
The botanical source, Ginkgo biloba, is the sole extant member of the order Ginkgoales and the family Ginkgoaceae. Ginkgo biloba (Ginkgoaceae) is well known as the oldest living plant species, often referred to as a "living fossil." G. biloba (Family Ginkgoaceae) is an important herb from the Chinese traditional system of medicine, and extract prepared from its leaves has been used in traditional medicine for several hundred years. The tree is an herbal product extracted from the leaves of the ginkgo tree, which grows throughout China, Korea, Japan, Europe, and the United States.
2. Chemical Composition of the Ginkgoheterosides Fraction
Ginkgoheterosides are flavonoid glycosides, meaning they are composed of a polyphenolic aglycone (the flavonol nucleus — quercetin, kaempferol, or isorhamnetin) attached to one or more sugar residues (typically glucose, rhamnose, or their combinations). The flavonoid glycosides are primarily composed of quercetin, kaempferol, and isorhamnetin glycosides, with major constituents including flavonol monoglycosides (e.g., quercetin-3-O-glucoside, quercetin-3-O-rhamnoside, and 3′-O-methylmyricetin-3-O-glucoside), flavonol diglycosides, flavonol triglycosides, and coumaric esters of flavonol diglycosides.
A review summarizing the reported chemical constituents from ginkgo biloba leaf and extract noted that to date about 110 flavonoids have been reported to have unambiguous structures, including flavonol and its glycosides, flavone and its glycosides, flavanone and its glycosides, isoflavone and its glycosides, flavan-3-ols, bioflavonoids, and biginkgosides.
The ginkgoheterosides fraction co-occurs in the leaf with a distinct second class of bioactive compounds, the terpene trilactones (ginkgolides A, B, C, J, and bilobalide), and with smaller quantities of organic acids, biflavones, proanthocyanidins, and catechins. The terpene trilactone group is represented by diterpene lactone ginkgolides A, B, C, J, K, L, and M, and sesquiterpene lactone bilobalide. Ginkgolides and bilobalide are unique terpenoid components found solely in the Ginkgo biloba L. tree. Other constituents such as glucose, rhamnose, hydroxykynurenic, kynurenic, protocatechuic, vanillic, and shikimic acids, d-glucaric acid, ginkgolic acid, and related alkylphenols have also been isolated.
According to an analysis of crude extracts of Ginkgo biloba leaves, there are seasonal differences in the levels of certain constituents, with concentrations of flavonol glycosides higher in the spring than in the autumn (136.3 mg/100 g versus 46.0 mg/100 g) and biflavones higher in the autumn than in the spring (194.8 mg/100 g versus 44.28 mg/100 g). Ginkgo biloba seedlings up to five years old contain more flavonoids and terpenoids than adult trees. Therefore, young leaves are used to produce standardized extract EGb761. With the age of trees, the content of biologically active ingredients decreases, and with it the quality of extracts produced from them.
3. Standardization: Pharmacopoeial and Commercial Specifications
Ginkgoheterosides — as the flavonol glycosides fraction — are central to the standardization of all pharmacopoeial and regulated ginkgo extract preparations. The most rigorously studied and widely used preparation is EGb 761® (Dr. Willmar Schwabe Pharmaceuticals, Karlsruhe, Germany). EGb 761 is a standardized extract of dried leaves of Ginkgo biloba containing 24% ginkgo-flavonol glycosides and 6% terpene lactones such as ginkgolides A, B, C, J, and bilobalide.
The EGb 761® extract is constituted of 5–10% organic acids, 24% flavonol glycosides, and 6% terpene trilactones (3.1% corresponding to ginkgolides A, B, C, and J, and 2.9% consisting of bilobalide). A second pharmaceutical extract, LI 1370, is manufactured by a similar process. Commercial extracts of the dried leaves of Ginkgo biloba for therapeutic use against neurodegenerative and cardiovascular diseases (EGb761 and LI1370) are standardized in a multi-step procedure designed to concentrate the desired active fractions of the plant extract.
Pharmacopoeial specifications vary by jurisdiction. The European Pharmacopoeia requires that dried G. biloba leaf is to be extracted with 60% acetone (m/m) as primary extraction solvent, and the final product is adjusted to 22.0%–27.0% ginkgo flavonoids calculated as ginkgo flavone glycosides, and 5.4%–6.6% terpene lactones consisting of 2.8%–3.4% ginkgolides A, B, C, and 2.6%–3.2% bilobalide, and contains less than 5 ppm ginkgolic acids. The U.S. specification for flavonol glycosides and ginkgolic acids is the same as the European, but the specification for terpene trilactones can be 5.4%–12.0%. The Chinese pharmacopoeia specifies only lower limits of at least 6% terpene trilactones and at least 24% flavonol glycosides with no upper limits.
Bioactive ingredients are obtained using a chemical method employing an acetone-water mixture to extract and concentrate the active substances and remove toxic metabolites such as ginkgolic acids. The extract contains 22%–27% flavonoid glycosides, 5%–7% terpene lactones, and <5 ppm ginkgolic acids. The flavonoid glycosides are generally recognized as a major ingredient in the extract, with commercial manufacturers often standardizing the sold product to a flavonoid glycoside content of 24%.
4. Common Forms and Preparations
Ginkgoheterosides are not commercially sold in isolation; they reach the consumer as part of ginkgo leaf extract preparations. Ginkgo is available as tincture, capsules, tablets, decoction, and standardized extract — usually in solid form. The standardized extract is the most well-researched preparation and contains 24% to 32% flavonoids and 6% to 12% terpenoids.
In clinical research and in regulated markets, the standardized dry extract (EGb 761® or similarly specified extract) is the predominant form studied. An injectable form is also used in China: extracts of Ginkgo biloba (EGB) are among the most common and earliest industrialized herbal medicinal preparations, and as a pharmaceutical brand of EGB, Shuxuening injection (SXNI) is approved by the Sino Food and Drug Administration, with its major identified active ingredients consisting of ginkgo flavonol glycosides (GFGs) and ginkgolides (GGs).
Ginkgo biloba is one of the most consumed medicinal plants and is broadly included as an ingredient in plant food supplements (PFS) and herbal infusions, being a potential target for economically motivated adulteration. Quantitative real-time PCR is used to detect ginkgo DNA, while ultra-high performance liquid chromatography with tandem mass spectrometry detection (UHPLC-MS/MS) determines its main phytochemicals (terpene lactones and flavonol aglycones). Quality and authenticity of commercial ginkgo supplements therefore vary considerably, and independent verification of ginkgoheterosides content is important for meaningful assessment of supplementation.
5. Traditional and Historical Use
The medicinal use of Ginkgo biloba is deeply embedded in Chinese traditional medicine. The tree traces its origins back over 200 million years, and approximately 2,700 years of human use have been documented. Extracts from the leaves of Ginkgo biloba trees have been used therapeutically for centuries in traditional Chinese medicine, and in modern Chinese pharmacopoeias both the leaves and fruits are recommended for treating problems of heart and lungs.
Extracts from Ginkgo biloba have been used medicinally in TCM for thousands of years to treat circulatory problems, asthma, vertigo, fatigue, and tinnitus. In TCM classification, the leaf is known as bai guo ye (白果叶). In Traditional Chinese Medicine, Ginkgo biloba leaf (known as bai guo ye) has been used for centuries to support lung function, improve blood circulation, and enhance cognitive clarity. Its seeds have been used as snacks and medical materials in Traditional Chinese Medicine, while over the last century its leaf extracts emerged as a source of rising pharmaceutical commerce related to brain health in Western medicine.
The seeds of the tree carry a separate and older medicinal tradition within China. A 16th-century Chinese text, the Ben Cao Gang Mu by Li Shi-Zhen, records the ancient prescription of ginkgo seeds for skin infections. Chinese Materia Medica (Ben Cao) refers to the botanical, mineral, and zoological substances used in TCM, and its oldest record (Wu Shi Er Bing Fang) dates back to approximately 1100 BCE and includes 247 natural agents and roughly 150 combinatorial drug formulae. In the methods of preparation recorded by Li Shi-Zhen, applying the paste of raw ginkgo kernels to the affected area, or rubbing (sliced-open) raw kernels on it, was described.
Its seeds have been applied in various therapeutic settings, often associated with respiratory health. Ancient practitioners utilized these seeds primarily to address issues such as asthma and stubborn coughs. Traditional practitioners recognized ginkgo's affinity for the upper body, particularly the lungs and brain. The leaves were often prepared as decoctions or combined with other herbs in formulas designed to "open the orifices" of the mind, a traditional description for enhancing mental clarity and memory.
Phytopharmaceutical extracts from the leaves of Ginkgo biloba have been applied to treat cerebrovascular and peripheral vascular diseases in many countries, such as Germany, France, Japan, and Korea since the 1960s. The transition from traditional whole-plant use to highly standardized pharmaceutical extracts defined by their ginkgoheterosides and terpene lactone content took place primarily in Germany and France during this period. In the early 1970s, Dr. Willmar Schwabe Pharmaceuticals effectively developed a method for the extraction and standardization of Ginkgo biloba extract preparation and produced highly concentrated and stable extracts from Ginkgo biloba leaves.
6. Key Active Constituents and Mechanisms of Action
6.1 Overview of the Two Major Active Fractions
The pharmacological activity of ginkgo leaf extract, and by extension of its ginkgoheterosides fraction, is considered to arise from the synergistic actions of two principal chemical classes: the flavonol glycosides (ginkgoheterosides) and the terpene trilactones (ginkgolides and bilobalide). EGb 761® has numerous pharmacological actions that derive from the various constituents of the herbal extract, acting separately or synergistically. The most pharmacologically important constituents in the treatment of cognitive decline are the flavonoid glycosides and terpene trilactones.
6.2 Mechanisms of the Ginkgoheterosides (Flavonol Glycosides) Fraction
Antioxidant and Free Radical Scavenging Activity. The ginkgoheterosides are most firmly established as potent polyphenolic antioxidants. As experiments have demonstrated, flavone glycosides and flavonol glycosides are potent antioxidants that scavenge oxygen free radicals, thereby preventing age-related cell and tissue damage that can adversely affect various mental functions, including memory and concentration. Ginkgolides have been specifically shown to act as platelet-activating factor (PAF) antagonists, inhibiting platelet aggregation and stimulating blood flow. Flavonoids are known to act as major antioxidants among various polyphenols and also act as heavy metal chelators due to their phenolic structures.
The antioxidant effect of flavonoids may result directly from increased activity of the cytochrome P-450 enzyme system, which reduces the formation of reactive oxygen species (ROS) and inhibits the release of peroxide anions.
Improvement of Peripheral Circulation. In addition, the flavone glycosides and flavonol glycosides increase peripheral circulation. This vasodilatory and hemodynamic effect is regarded as a key contributor to the extract's vascular indications.
Anti-inflammatory Activity. Ginkgo flavonoids and their glycosides exhibit multidirectional biological activity, including antioxidant, anti-cancer, anti-bacterial, anti-viral, anti-inflammatory, and neuroprotective properties. At the molecular level, the ginkgo extract and its flavonoid constituents have been shown to inhibit pro-inflammatory signaling. The possible mechanisms of ginkgo biloba leaves in treating neurological disorders are mainly through free radical scavenging, anti-oxidant activity, anti-inflammatory response, mitochondrial protection, neurotransmitter regulation, and antagonism of PAF.
Neuroprotection and Amyloid Modulation. It has been reported that GBE inhibits the production of Aβ in the brain by lowering the levels of circulating free cholesterol, as AβPP processing and amyloidogenesis are supposed to be affected by free circulating and intracellular cholesterol levels. Despite this evidence, further investigations are needed to identify the major constituents responsible for this anti-amyloidogenic effect. Anti-oxidation, anti-inflammation, anti-apoptosis, defense against mitochondrial dysfunction, amyloidogenesis and Aβ aggregation, modulation of phosphorylation of tau protein, ion homeostasis, and even induction of growth factors are possible mechanisms of action of GBE.
6.3 Mechanisms of the Terpene Lactone (Ginkgolide) Co-Fraction
While not ginkgoheterosides themselves, the terpene trilactone co-fraction shapes the pharmacological profile of all standardized extracts, and both fractions are always present together in commercial preparations. The formulation of EGb 761 consists of the trilactone terpenes, ginkgolides A, B, and C, and flavonoids present as flavonol-O-glycosides. Ginkgolides have been clinically shown to act as platelet-activating factor (PAF) antagonists, inhibiting platelet aggregation and promoting increased blood flow. Flavonoids are known as antioxidants and heavy metal chelators due to their phenolic structures, and they have been clinically investigated in cardiovascular and inflammatory diseases.
The five known ginkgolides, ginkgolides A, B, C, J, and M, have a cage-like molecular structure with six five-membered rings and a tert-butyl group, and differ in the position and number of substituted hydroxyl groups on the spirononane framework. Ginkgo terpene lactones are terpenoid representatives of PAF receptor antagonists extracted from Ginkgo biloba leaves. A number of different ginkgolides have been identified and labeled as A, B, C, K, J, L, M, N, P, and Q. Among these, A, B, C, and K are the main active compounds of PAF receptor antagonists that are essential in treating cardiovascular and cerebrovascular diseases.
6.4 Differential Contributions of the Two Fractions
In a myocardial ischemia–reperfusion injury model, pretreatment with ginkgo flavonol glycosides at 2.5 ml/kg was superior to the same dose of ginkgolides in improving cardiac function and coronary blood flow and reducing the levels of lactate dehydrogenase and aspartate aminotransferase in serum, with an effect similar to that achieved by the combined Shuxuening injection. Conversely, studies examining cortical recovery from hemiplegia found that both extracts of the reference product (EGb761-IPSEN) produced a dose-dependent acceleration of behavioral recovery, and these results indicated that the active substance(s) participating in the beneficial effect of EGb761 is (are) contained in the non-terpenic fraction of the extract.
Various mechanisms are associated with the neuroprotective effect of EGb 761®, including free radical-scavenging, antioxidant effects, improvement in mitochondrial function, regulation of neurotransmitters, and effects on neuronal plasticity. Preliminary results with EGb 761® in adults with memory impairment suggest mild enhancement of prefrontal dopamine.
7. Scientific Evidence by Area of Use
7.1 Cognitive Function, Dementia, and Alzheimer's Disease
This is the area of most extensive clinical investigation. Alzheimer's disease (AD) is a common neurodegenerative disease, mainly manifested by cognitive dysfunction, and there is no ideal treatment strategy in clinical practice. Clinical studies on the treatment of AD with Ginkgo biloba L. leaf extract (EGb) have been reported since the 1980s, and many clinical studies have been carried out during the following 30 years. However, the benefits of EGb on the treatment of AD are still controversial.
A systematic review and meta-analysis published in the Journal of Alzheimer's Disease (Tan et al., 2015) searched MEDLINE, EMBASE, Cochrane, and other databases for randomized controlled trials of EGb761 in patients with cognitive impairment and dementia. Nine trials met the inclusion criteria. Trials were of 22–26 weeks duration and included 2,561 patients in total. In the meta-analysis, the weighted mean differences in change scores for cognition were in favor of EGb761 compared to placebo (−2.86, 95% CI −3.18; −2.54); the standardized mean differences in change scores for activities in daily living were also in favor of EGb761 compared to placebo (−0.36, 95% CI −0.44; −0.28). In subgroup analysis in patients with neuropsychiatric symptoms, 240 mg/day EGb761 improved cognitive function, ADLs, clinician global impression of change (CGIC), and also neuropsychiatric symptoms with statistical superiority compared to the whole group.
A meta-analysis of 13 studies meeting inclusion criteria (duration 12–52 weeks, daily dose more than 120 mg) using the extract EGb761 was performed with 2,381 total patients and used the Syndrome Kurztest (SKT), the Alzheimer's Disease Assessment Scale Cognitive Subscale (ADAS-Cog), or clinical global impression as efficacy parameters. Thirteen studies using EGb761 met the inclusion criteria, which were duration of 12 to 52 weeks and daily dose of more than 120 mg, and included a total of 2,381 patients. Meta-analysis was performed using 9 of 13 studies, 7 of which used the SKT and 2 ADAS-Cog scores as efficacy parameters.
A 2025 meta-analysis examining EGb 761 specifically in patients with mild dementia reported that patients with mild dementia benefit from EGb 761 in terms of cognition, activities of daily living, global assessment, and quality of life. That analysis was restricted to randomized, placebo-controlled trials meeting the inclusion criteria of mild or mild-to-moderate dementia, duration of at least 20 weeks, and dosage of 240 mg daily.
A review by Frontiers in Pharmacology (2019) considered the overall body of clinical evidence and concluded that EGb may be able to improve cognitive function in patients who suffer from mild dementia during long-term administration (more than 24 weeks) and at an appropriate dosage (240 mg per day).
A prospective observational study conducted by Amieva et al. (2013) which involved 3,612 patients aged over 65 from the South of France highlighted a slower progression of cognitive impairment in the EGb 761® group of patients than in the piracetam group.
Regarding large prevention trials, multiple large, well-designed randomized controlled trials — including studies with over 3,000 participants followed for up to six years — have failed to demonstrate that ginkgo prevents dementia, slows cognitive decline, or meaningfully improves memory in healthy adults. The NCCIH (National Center for Complementary and Integrative Health, U.S. National Institutes of Health) accordingly notes that "there's no conclusive evidence that ginkgo is helpful for any health condition."
Overall assessment: Evidence from multiple meta-analyses of RCTs suggests that standardized EGb 761 at 240 mg/day over 22–26 weeks shows statistically significant benefits for cognition and daily living in patients with established mild to moderate dementia, including Alzheimer's and vascular dementia subtypes. Evidence for prevention of dementia onset in cognitively healthy adults is not established. Effect sizes are modest and the clinical significance remains debated.
7.2 Cardiovascular and Cerebrovascular Disease
In the last decades, Ginkgo biloba has been used clinically for the prevention and treatment of different cardiovascular diseases, including hypertension, cerebrovascular disease, peripheral arterial disease, peripheral venous disease, Raynaud's phenomenon, and erectile dysfunction.
This plant displays myocardial suppressant and vasorelaxant activities ex vivo. It improves perfusion in different vascular beds without significantly affecting blood pressure and heart rate. Its broad spectrum of pharmacological activities allows it to be in adequacy to the numerous pathological requirements — hemodynamic, hemorheological, metabolic — which occur in cerebral, retinal, cochleovestibular, cardiac, or peripheral ischemia.
However, the overall clinical picture for cardiovascular disease prevention is not positive. A large trial (the Ginkgo Evaluation of Memory study, GEMS) found no evidence that G. biloba reduced total or CVD mortality or CVD events, while there were more peripheral vascular disease events in the placebo arm. G. biloba cannot be recommended for preventing CVD. For hypertension, a recent systematic review and a meta-analysis have both reported that Ginkgo biloba does not show higher efficacy than placebo, with an exception in elderly patients with dementia.
An injectable ginkgo preparation is used in clinical practice in China for acute ischemic stroke. Evidence suggests that the diterpene ginkgolide meglumine injection (DGMI) has an antiplatelet effect and can improve the prognosis of acute ischemic stroke (AIS) patients.
Overall assessment: Preclinical and mechanistic evidence for vascular effects is well established. Large RCTs have not demonstrated benefit for general cardiovascular event prevention. Some signal exists for peripheral vascular disease outcomes and acute ischemic stroke (via injectable preparations), but further evidence is needed.
7.3 Tinnitus and Vertigo
Ginkgo biloba in the form of EGb 761 (standard Ginkgo biloba leaf extract containing 24% of glycoside flavonoids and 6% of terpene lactones) is the most widely prescribed dietary supplement for peripheral vascular disease and cerebral insufficiency that causes concentration difficulties, memory loss, dizziness, and tinnitus.
For tinnitus, the clinical evidence is not favorable. A Cochrane review in 2013, which included four trials with a total of 1,543 participants, demonstrated that there was no evidence that Ginkgo biloba was effective in patients with a primary complaint of tinnitus. Standardized ginkgo biloba extract (GBE) is an established herbal treatment used for a variety of indications including tinnitus and vertigo; however, the evidence base in human clinical studies for a clear benefit of GBE in vertigo and/or tinnitus is limited and contradictory due to poor reporting as well as variations in study quality and outcome measures used.
For vertigo, some controlled trial evidence is more encouraging, though the evidence base remains limited. Vertigo appears to be one of the more promising indications for ginkgo, with two clinical trials showing meaningful improvements at doses of 160 mg/day over 3 months. However, both studies are relatively old and small, and the evidence base is not as robust as would be ideal.
Overall assessment: Tinnitus as a primary complaint lacks supporting clinical evidence (Cochrane level). Evidence for vertigo is preliminary, limited to small older trials, and cannot be considered robust.
7.4 Neuropsychiatric and Other Neurological Disorders
Out of 1,385 records in a systematic database, 52 were screened in relation to the function of Ginkgo biloba leaves in the treatment of neurological disorders; of these 52, 39 were preclinical trials and 13 were clinical studies. Analysis of pharmacological studies revealed that ginkgo biloba leaves can improve memory, cognition, behavior, and psychopathology, and that the most frequently associated conditions are depression, followed by Alzheimer's disease, stroke, Huntington's disease, and Parkinson's disease. The clinical studies of depression, AD, and stroke are the most common, and most of the remaining neurological disorder data are available from in vitro or in vivo animal studies.
EGb has a broad range of pharmacological effects, including anti-inflammation, antioxidant, anti-apoptotic, antidepressant, anti-arrhythmia, antitumor activity, improving cognitive function, and relieving ischemia/reperfusion injury. However, for most of these indications beyond dementia and stroke, the clinical evidence remains predominantly at the preclinical (in vitro and animal) stage.
7.5 Ischemia–Reperfusion Injury (Myocardial and Cerebral)
Shuxuening injection (SXNI), one of the pharmaceutical preparations of Ginkgo biloba extract, has significant effects on both ischemic stroke and heart diseases from bench to bedside. Its major active ingredients are ginkgo flavonol glycosides (GFGs) and ginkgolides (GGs). The ginkgo flavonol glycosides fraction in particular showed differential efficacy in myocardial ischemia–reperfusion: pretreatment with GFGs at 2.5 ml/kg was superior to the same dose of GGs in improving cardiac function and coronary blood flow and reducing the levels of lactate dehydrogenase and aspartate aminotransferase in serum.
Overall assessment: Evidence for ischemia–reperfusion benefit from injectable preparations is strongest in Chinese clinical literature. These preparations are not currently available in Western markets in injectable form, and the translational value of this body of evidence to Western oral-supplementation contexts requires further evaluation.
8. Body Systems and Health Areas of Association
- Central nervous system: Cognitive function, memory, dementia (Alzheimer's and vascular subtypes), neuropsychiatric symptoms, depression, neuroprotection in stroke and neurodegenerative disease.
- Cardiovascular and cerebrovascular system: Peripheral arterial disease, peripheral vascular circulation, myocardial ischemia–reperfusion protection, reduction of blood viscosity, PAF-mediated platelet aggregation.
- Special senses: Tinnitus (inner ear blood flow), vertigo (cochleovestibular perfusion), and age-related ocular conditions (macular degeneration, diabetic retinopathy) though clinical evidence for ocular indications is limited.
- Respiratory system: Traditional use for asthma and cough (seeds); not a major focus of modern phytopharmaceutical research.
- Inflammatory and immune system: Anti-inflammatory activity via NF-κB and related signaling pathway inhibition, particularly studied in the context of neuroinflammation.
- Musculoskeletal system: Emerging research context: Ginkgo biloba extract (EGb 761) has demonstrated anti-inflammatory, antioxidant, anti-apoptotic, and chondroprotective activity relevant to osteoarthritis, though human clinical data in this area are limited.
9. Dosage Forms and Dosages Reported in Studies
All dosage information below is drawn directly from the referenced studies and pharmacopoeial/clinical literature.
- Standard clinical dose (EGb 761, oral): The standard clinical dose of EGb 761 is 120 mg (~1.7 mg/kg) once or twice daily; thus, a standard dose will contain approximately 3–4 mg ginkgolides A, B, and C, 3–4 mg bilobalide, and 29 mg flavonoids.
- Dementia treatment dosage: Pre-established inclusion criteria for the 2025 meta-analysis required mild or mild-to-moderate dementia, duration of at least 20 weeks, and dosage of 240 mg daily.
- Cognitive function (Frontiers in Pharmacology, 2019 review): EGb may be able to improve cognitive function in patients with mild dementia during long-term administration (more than 24 weeks) and at an appropriate dosage (240 mg per day).
- Vertigo (reported doses): Two clinical trials showing meaningful improvements in vertigo used doses of 160 mg/day over 3 months.
- Higher dose evidence: Some evidence suggests that a higher dose (240 mg per day) may be more beneficial than the typical (120 mg per day) dose for vestibular and vascular indications.
- Neuropsychiatric symptoms subgroup (Tan et al. meta-analysis): For subgroup analysis in patients with neuropsychiatric symptoms, 240 mg/day EGb761 improved cognitive function, ADLs, CGIC, and also neuropsychiatric symptoms with statistical superiority than for the whole group.
- Included trial durations (Tan et al., 2015): Nine trials met inclusion criteria. Trials were of 22–26 weeks duration and included 2,561 patients in total.
10. Safety Considerations and Drug Interactions
10.1 General Safety Profile
Safety data from the Tan et al. meta-analysis revealed no important safety concerns with EGb761. EGb 761® is generally well tolerated, with no safety issues being identified during its many years of widespread use. It displays an acceptable safety profile, with most reported adverse reactions constituting rare occurrences.
10.2 Ginkgolic Acid Toxicity
The principal toxicity concern with ginkgo-containing products relates not to the ginkgoheterosides fraction per se, but to ginkgolic acids — alkylphenol contaminants found especially in crude and non-standardized leaf preparations. Structurally similar to the irritants in poison ivy, ginkgolic acids are the factors responsible for toxic effects of Ginkgo biloba extracts, including gastrointestinal disturbances, headaches, skin irritation, dermatitis, and edema. Ginkgolic acids are alkylphenols found in the fruits and leaves of Ginkgo biloba. A close correlation was observed between the concentration of ginkgolic acids and the cytotoxicity of the extracts — the extract containing the lowest concentration of ginkgolic acids displayed the highest IC50 values in treated cells, indicating a low toxic potential. The IC50 values of the extracts showed 22–63-fold differences between the extracts with the lowest and highest ginkgolic acid content. Pharmacopoeial specifications address this by limiting ginkgolic acids to less than 5 ppm in regulated extracts.
10.3 Seizure Risk (Ginkgotoxin, Seeds)
Seizure risk from ginkgo preparations is primarily associated with the neurotoxin ginkgotoxin (4-O-methylpyridoxine) found in the seeds, not in standardized leaf extracts. A 64-year-old woman developed symptoms of vomiting and tonic-clonic convulsions 9.5 hours after eating 50 roasted Ginkgo biloba seeds with 100 g of alcohol. The seed is not the source of ginkgoheterosides used in standardized supplements, and this risk does not apply to pharmacopoeially standardized leaf extracts in usual doses. However, ginkgotoxin has also been identified in small amounts in leaves, and ginkgotoxin, which induces epileptic seizures, is found in G. biloba. Case reports of seizures attributed to leaf extract products in persons with pre-existing seizure disorders have been published.
10.4 Anticoagulant and Antiplatelet Drug Interactions
The interaction between ginkgo biloba and warfarin or antiplatelet agents is a clinically documented concern with conflicting evidence across the literature. Ginkgo biloba is a widely used herbal product that could potentially have a severe interaction with warfarin, which is the most frequently prescribed anticoagulant agent in North America. Literature, however, provides conflicting evidence on the presence and severity of the interaction.
A large retrospective cohort study of a Veterans Administration clinical database found that taking ginkgo concurrently with warfarin significantly increased patients' risk of a bleeding adverse event (hazard ratio = 1.38, 95% CI: 1.20 to 1.58, p < 0.001). Conversely, a systematic review of controlled clinical studies concluded that results from controlled studies consistently indicate that ginkgo does not significantly impact haemostasis nor adversely affect the safety of coadministered aspirin or warfarin. A Cochrane-level evaluation of hemostasis parameters found that a systematic review and meta-analysis of 18 randomized controlled trials looked at the impact of ginkgo on hemostasis parameters associated with bleeding risk and found a significant reduction in blood viscosity; however, there were no effects on other factors such as ADP-induced platelet aggregation, fibrinogen concentration, activated partial thromboplastin time, and prothrombin time.
An in-vivo mechanistic study in mice found that neither GBE (up to 1000 mg/kg) nor ginkgolide B (up to 140 mg/kg), a platelet-activating factor antagonist, influenced blood coagulation parameters.
A pharmacovigilance study from Vietnam (Hai Phong International Hospital, 2022–2023) examined 2,647 prescriptions and found that out of 2,647 prescriptions meeting the inclusion criteria, 342 exhibited drug interactions, a prevalence rate of 12.94%. Ginkgo biloba extract frequently interacts with antiplatelets, anticoagulants, and nonsteroidal anti-inflammatory drugs, with clopidogrel and aspirin exhibiting the highest prevalence rates of 2.61% each.
A clinical update on herb-warfarin interactions classified ginkgo among those herbs warranting serious attention: among 38 herbs evaluated, cannabis, chamomile, cranberry, garlic, ginkgo, grapefruit, lycium, red clover, and St. John's wort were evaluated to have major severity interaction with warfarin.
When analyzing adverse drug–herb interactions, it is generally difficult to conclude whether the cause was a certain herbal ingredient itself or a combination of the many ingredients contained within a herbal product. Moreover, idiosyncratic reactions or side effects of drugs taken simultaneously may be involved in adverse events.
10.5 CYP Enzyme Interactions
Ginkgo biloba can affect the metabolism and efficacy of co-administered drugs through CYP450 modulation and platelet function alteration. Component-level research has found that ginkgolide A can influence CYP1A2, and the constituent bilobalide has been specifically implicated in cytochrome P-450 induction: one mouse study found that bilobalide induced hepatic CYP enzymes, potentially attenuating warfarin's anticoagulant effect.
10.6 Other Noted Safety Signals
The clinical efficacy of EGb761 still remains elusive. Multiple factors such as population sensitivity, severity of impairment, type of assessments used to measure efficacy, and doses were suggested to be able to interfere with EGb761's efficacy in clinical practice. Variability in commercial product quality is also a well-recognized concern: an analysis of five commercial ginkgo products found that the five samples had 6%–11% terpene lactones and 28%–35% flavonoids; however, the individual amounts of specific compounds within each class varied by as much as 200% between the different products.
11. Regulatory and Quality Context
The German government approved a standardized form of ginkgo leaf extract (i.e., EGb 761). Ginkgo biloba leaf extract is listed in the European Pharmacopoeia, the United States Pharmacopeia (USP), and the Chinese Pharmacopoeia, each with specific analytical requirements for the ginkgoheterosides fraction. The ESCOP (European Scientific Cooperative on Phytotherapy) and German Commission E have also issued formal monographs establishing the therapeutic use of standardized ginkgo leaf extract.
The combination of a unique blend of plant material of highest possible quality and a unique patented extraction process capable of adjusting concentrations of major ingredients results in a final product of unique composition with a very high batch-to-batch consistency. Due to the multidimensionality of all these parameters, it is virtually impossible to produce an extract of the same composition by other manufacturers. This caveat is important when interpreting clinical trial results: findings from EGb 761® trials may not be directly applicable to all commercial ginkgo products. Out of a total of 19 plant food supplement samples tested for authentication, four were found to be adulterated, with two samples evidencing the addition of quercetin from sources other than ginkgo.
References
Go back